ABSTRACT
BACKGROUND: Tubeimoside-1 (TBMS1), a triterpenoid saponin extracted from traditional Chinese medicine tubeimoside, exerts a cytotoxic effect on several human cancer cell lines. However, no study has focused on whether TBMS1 works on oral squamous cell carcinoma (OSCC). MATERIALS AND METHODS: We treated OSCC cells with TBMS1 to detect the effect and relevant molecular basis of TBMS1 for the first time. We chose two oral cancer cell lines, CAL27 and SCC15, for this study. First, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-trazolium bromide assay and cell proliferation 5'-bromo-2'-deoxyuridine assay were carried out to detect cell growth. Second, colony formation assay was performed to assess clonogenesis capacity. Next apoptosis was analyzed by flow cytometry. Subsequently, wound healing and transwell assays were applied to explore cell migration. Finally, Western blot was further performed to examine corresponding proteins' expression change. RESULTS: Our data showed that TBMS1 significantly suppressed proliferation of OSCC cells in a dose- and time-dependent manner and it inhibited migration of OSCC cells as well. After treatment with TBMS1, OSCC cells underwent cell apoptosis. Furthermore, Western blot demonstrated that TBMS1 downregulated apoptosis-associated proteins such as PARP, p-ERK1/2, Bcl-2, caspase-3, caspase-7 and caspase-8 and upregulated cleaved PARP, cleaved caspase-3 and cleaved caspase-9. It could also reduce expression of c-Myc and MMP-7. Meanwhile, TBMS1 did not change the total ERK1/2 expression. CONCLUSION: These results revealed that TBMS1 might be a potential chemotherapeutic drug for the management of OSCC.
ABSTRACT
PURPOSE: To systematically review the association between interleukin-10 (IL-10) -1082G/A gene polymorphism and susceptibility of recurrent oral ulcer (ROU) by meta analysis. METHODS: Databases of PubMed, Embase, Web of Science, CNKI, CBM, WanFang, and VIP were electronically searched to collect studies published up to August 2017 about the association between IL-10-1082G/A gene polymorphism and ROU susceptibility. According to the inclusion and exclusion criteria, two reviewers independently screened literature and extracted data, the methodological quality assessment and heterogeneity test of included studies were performed. Meta analysis was performed with RevMan5.3 software. RESULTS: A total of 6 case-control studies were included, which involved 668 ROU patients in case group and 769 healthy individuals in control group. In the general population, the results of meta analysis showed that, under 3 genetic models including allele model (G vs A), recessive model (GG+GA vs AA) and heterozygous model (GA vs AA), there was significant association between IL-10-1082G/A gene polymorphism and ROU susceptibility (G vs A: OR=1.31, 95%CI 1.03 to 1.66, P=0.03; GG+GA vs AA: OR=1.45, 95%CI 1.16 to 1.82, P=0.001; GA vs AA: OR= 1.33, 95%CI 1.04 to 1.70, P=0.02). In the Asian population, meta analysis result was consistent with the general population. CONCLUSIONS: IL-10-1082G/A gene polymorphism is associated with ROU susceptibility. Individuals with G allele and GA genotype have a higher risk of ROU. Future more well-designed, large sample and multicenter studies are greatly needed to verify our conclusion.
